Compare Regeneron Pharmaceuticals Inc (REGN) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Snap Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B), while Snap Inc trades at $5.89 (market cap $9.83B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7.8× Snap Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Snap Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Snap Inc for 68 Days on average.
| REGN | SNAP | |
|---|---|---|
Market Cap | $76.40B | $9.83B |
Volume | 626,381 | 28,532,342 |
Sector | Health | Media |
52-Week High | $852.03 | $9.09 |
52-Week Low | $557.73 | $3.93 |
Typical Hold Time | 107 Days | 68 Days |
Enterprise Value | $71.12B | $11.39B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Snap Inc. (SNAP) trades at $5.865, up 1.12% with a bullish technical signal. Revenue grew to $5.93B in 2025, though net losses persist at -$460M. Recent news highlights AI integration in SPECS glasses via partnerships with NVIDIA and Salesforce. Analyst consensus is mixed with 38% buy ratings and a $7.78 price target.
Outlook: Potential upside exists from AI initiatives and revenue growth, but profitability challenges and high debt ($3.61B) pose risks. The stock's valuation (P/S 1.55) appears reasonable, yet investor caution is warranted amid regulatory pressures and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
